A Phase I Study of Vaccination with Autologous, Irradiated Melanoma Cells Engineered to Secrete Human Granulocyte-Macrophage Colony Stimulating Factor. Dana-Farber Cancer Institute, Boston, Massachusetts
- 1 January 1997
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 8 (1), 111-123
- https://doi.org/10.1089/hum.1997.8.1-111
Abstract
The only peer-reviewed journal focused on the rapidly moving field of 3D printing and related technologies, providing comprehensive coverage of academic research and industrial and commercial developments that have applications in medicine, education, food, and architecture.Keywords
This publication has 42 references indexed in Scilit:
- Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.The Journal of Experimental Medicine, 1993
- Recognition of shared melanoma antigen by HLA‐A2‐restricted cytolytic T cell clones derived from human tumor‐infiltrating lymphocytesEuropean Journal of Immunology, 1993
- A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.The Journal of Experimental Medicine, 1992
- Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma VaccineAnnals of Surgery, 1992
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991
- Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4Science, 1991
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.The Journal of Experimental Medicine, 1988
- Autologous lymph node cell-derived tumor-specific cytotoxic t-cells for use in adoptive immunotherapy of human melanomaCancer, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987